Cargando…

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers

Intrinsic or acquired resistance seriously limits the use of platinating agents in advanced epithelial ovarian cancers. Increased DNA repair capacity is a key route to platinum resistance. RAD50 is a critical component of the MRN complex, a ‘first responder’ to DNA damage and essential for the repai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alblihy, Adel, Alabdullah, Muslim L., Toss, Michael S., Algethami, Mashael, Mongan, Nigel P., Rakha, Emad A., Madhusudan, Srinivasan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607373/ https://www.ncbi.nlm.nih.gov/pubmed/35006434 http://dx.doi.org/10.1186/s43556-020-00023-y

Ejemplares similares

Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2022)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
por: Mesquita, Katia A., et al.
Publicado: (2021)

Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers
por: Algethami, Mashael, et al.
Publicado: (2023)

Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade
por: Alblihy, Adel, et al.
Publicado: (2023)

Towards Personalized Management of Ovarian Cancer
por: Algethami, Mashael, et al.
Publicado: (2022)

ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity
por: Ali, Reem, et al.
Publicado: (2019)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

The characteristics and clinical significance of atypical mitosis in breast cancer
por: Lashen, Ayat, et al.
Publicado: (2022)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer
por: Kariri, Yousif A., et al.
Publicado: (2022)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
por: Hoppe, Michal M, et al.
Publicado: (2021)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
por: Compadre, Amanda J., et al.
Publicado: (2023)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Mimivirus reveals Mre11/Rad50 fusion proteins with a sporadic distribution in eukaryotes, bacteria, viruses and plasmids
por: Yoshida, Takashi, et al.
Publicado: (2011)

Indistinguishable Landscapes of Meiotic DNA Breaks in rad50(+) and rad50S Strains of Fission Yeast Revealed by a Novel rad50(+) Recombination Intermediate
por: Hyppa, Randy W., et al.
Publicado: (2008)

Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer
por: Brandt, Simone, et al.
Publicado: (2017)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors
por: Yoon, Bo-Sung, et al.
Publicado: (2008)

Rad50 promotes ovarian cancer progression through NF‐κB activation
por: Li, Yinuo, et al.
Publicado: (2021)

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts()
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
por: Joseph, Chitra, et al.
Publicado: (2020)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

CDKN2A gene inactivation in epithelial sporadic ovarian cancer
por: Niederacher, D, et al.
Publicado: (1999)

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
por: Clark-Knowles, Katherine V., et al.
Publicado: (2010)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
por: Cantón-Romero, Juan Carlos, et al.
Publicado: (2017)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dgd4jgorvc056jh67tp3mrg8nv